SPCG Workshop 2026 highlights next steps in Prostate Cancer Research

Leading prostate cancer specialists from across the Nordic countries recently met at Holmenkollen, Oslo, for the SPCG (Scandinavian Prostate Cancer Group) Workshop 2026 to discuss how future care can become more precise, patient‑friendly, and efficient.

With survival rates now very high in the Nordics, the meeting focused on improving quality of life and avoiding unnecessary treatment. Researchers highlighted growing evidence that many patients can safely receive less intensive or more flexible treatments, including planned treatment breaks, without losing disease control.

Another key topic was earlier and smarter diagnosis. Participants explored how artificial intelligence may support doctors in interpreting prostate MRI scans, potentially reducing unnecessary biopsies and speeding up diagnosis. Plans were discussed for a large Nordic study to evaluate AI in real clinical settings.

The workshop also marked a shift in how research will be organized. Rather than long, isolated studies, SPCG aims to develop shared research platforms that allow new treatments, diagnostics, and biomarkers to be tested more quickly and efficiently across countries.

The meeting concluded with strong agreement to move several projects forward and to strengthen Nordic collaboration through focused working groups and regular follow‑up meetings.

The organizers would like to warmly thank the sponsor Astellas for funding the workshop, which made it possible to bring together experts from multiple countries for open discussion and collaboration.

Participants of the SPCG Workshop gathered at Holmenkollen to discuss and strengthening Nordic collaboration in prostate cancer research.